Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo.

@article{Graff2008SignificantEO,
  title={Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo.},
  author={Jochen Graff and Nils von Hentig and Karina Kuczka and Carlo Angioni and Peter Gute and Stefan Klauke and Errol Babacan and S. Harder},
  journal={The Journal of antimicrobial chemotherapy},
  year={2008},
  volume={61 2},
  pages={394-9}
}
OBJECTIVES In the past, bleeding events have been described for patients with haemophilia taking HIV-1 protease inhibitors. Recently, the FDA published a warning concerning intracranial haemorrhage in patients taking the HIV-1 protease inhibitor tipranavir co-administered with ritonavir. METHODS We investigated (i) platelet aggregation in vivo in HIV-1-infected adult patients (n = 5) immediately before and 2 and 4 h after dosing of tipranavir/ritonavir 500/200 mg. To further characterize the… CONTINUE READING